Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

NCT07738276 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Heart Failure and Reduced Ejection Fraction
Obesity & Overweight
Tirzepatide

Interventions

DRUG: Tirzepatide
DRUG: Placebo

Sponsor

Shahid Beheshti University of Medical Sciences

Collaborators

[object Object]